Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million

Reuters

Feb 12

Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million

Vanda Pharmaceuticals Inc. reported financial results for the periods ended December 31, 2025. For the fourth quarter, Fanapt net product sales reached USD 33.22 million, while HETLIOZ net product sales totaled USD 16.39 million. For the full year 2025, Fanapt net product sales amounted to USD 117.30 million and HETLIOZ net product sales were USD 94.30 million. The company provided non-GAAP financial information, excluding a one-time, non-cash valuation allowance income tax charge, to assist investors in assessing its ongoing business performance. Vanda Pharmaceuticals stated that these adjustments better reflect the recurring economic characteristics of its operations and long-term performance. Additional details, including reconciliations of non-GAAP to GAAP figures, are available through the company's public filings. Vanda Pharmaceuticals continues to focus on the development and commercialization of innovative therapies to address high unmet medical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH86159) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610286965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610286965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610286965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610286965","market":"nz","top_or_hot":-1,"title":"Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vanda Pharmaceuticals Inc. reported financial results for the periods ended December 31, 2025. For the fourth quarter, Fanapt net product sales reached USD 33.22 million, while HETLIOZ net product sales totaled USD 16.39 million. For the full year 2025, Fanapt net product sales amounted to USD 117.30 million and HETLIOZ net product sales were USD 94.30 million. The company provided non-GAAP financial information, excluding a one-time, non-cash valuation allowance income tax charge, to assist investors in assessing its ongoing business performance. Vanda Pharmaceuticals stated that these adjustments better reflect the recurring economic characteristics of its operations and long-term performance. Additional details, including reconciliations of non-GAAP to GAAP figures, are available through the company's public filings. Vanda Pharmaceuticals continues to focus on the development and commercialization of innovative therapies to address high unmet medical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH86159) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vanda Pharmaceuticals Inc. reported financial results for the periods ended December 31, 2025. For the fourth quarter, Fanapt net product sales reached USD 33.22 million, while HETLIOZ net product sales totaled USD 16.39 million. For the full year 2025, Fanapt net product sales amounted to USD 117.30 million and HETLIOZ net product sales were USD 94.30 million. The company provided non-GAAP financial information, excluding a one-time, non-cash valuation allowance income tax charge, to assist investors in assessing its ongoing business performance. Vanda Pharmaceuticals stated that these adjustments better reflect the recurring economic characteristics of its operations and long-term performance. Additional details, including reconciliations of non-GAAP to GAAP figures, are available through the company's public filings. Vanda Pharmaceuticals continues to focus on the development and commercialization of innovative therapies to address high unmet medical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH86159) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL5xq7d6:1","article_id":"2610286965","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610286965","pubTimestamp":1770843704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vanda Pharmaceuticals Inc. reported financial results for the periods ended December 31, 2025. For the fourth quarter, Fanapt net product sales reached USD 33.22 million, while HETLIOZ net product sales totaled USD 16.39 million. For the full year 2025, Fanapt net product sales amounted to USD 117.30 million and HETLIOZ net product sales were USD 94.30 million. The company provided non-GAAP financial information, excluding a one-time, non-cash valuation allowance income tax charge, to assist investors in assessing its ongoing business performance. Vanda Pharmaceuticals stated that these adjustments better reflect the recurring economic characteristics of its operations and long-term performance. Additional details, including reconciliations of non-GAAP to GAAP figures, are available through the company's public filings. Vanda Pharmaceuticals continues to focus on the development and commercialization of innovative therapies to address high unmet medical needs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VNDA":"万达生物制药"},"translate_title":"Vanda Pharmaceuticals第四季度非公认会计准则净亏损达1.0678亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNDA":0.9},"content_text":"Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million\n    \n\n        Vanda Pharmaceuticals Inc. reported financial results for the periods ended December 31, 2025. For the fourth quarter, Fanapt net product sales reached USD 33.22 million, while HETLIOZ net product sales totaled USD 16.39 million. For the full year 2025, Fanapt net product sales amounted to USD 117.30 million and HETLIOZ net product sales were USD 94.30 million. The company provided non-GAAP financial information, excluding a one-time, non-cash valuation allowance income tax charge, to assist investors in assessing its ongoing business performance. Vanda Pharmaceuticals stated that these adjustments better reflect the recurring economic characteristics of its operations and long-term performance. Additional details, including reconciliations of non-GAAP to GAAP figures, are available through the company's public filings. Vanda Pharmaceuticals continues to focus on the development and commercialization of innovative therapies to address high unmet medical needs.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH86159) on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}